EUVIMEDEUVIMED entdecken
Vergleichsstudie

Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients

Sydni Martinez iD, Devika Sindu iD, Michael D Nailor, Lauren Cherrier iD, Sofya Tokman iD, Rajat Walia iD, Kellie J Goodlet iD

Transplant Infectious Disease · 2024

DOI: 10.1111/tid.14279 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Sydni Martinez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Cytomegalovirus Infections, Valganciclovir, Antiviral Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung transplant recipients are at high risk for severe cytomegalovirus (CMV) disease. Off‐label use of letermovir (LET) may avert myelotoxicity associated with valganciclovir (VGCV), but data in lung transplantation are limited. This study aims to evaluate the outcomes of LET prophylaxis among lung transplant recipients.

Methods

This retrospective, matched cohort study included lung transplant recipients who received LET for primary CMV prophylaxis following VGCV intolerance. Patients were matched 1:1 to historical VGCV controls based on age, serostatus group, and time from transplant. The primary outcome was CMV breakthrough within 1 year post‐LET initiation; secondary outcomes included hematologic changes.

Results

A total of 124 lung transplant recipients were included per group (32% CMV mismatch, D+R‐), with LET initiated a median of 9.6 months post‐transplantation. One CMV breakthrough event (0.8%) was observed in the LET group versus four (3.2%) in the VGCV group ( p = .370). The median (interquartile range) white blood cell (WBC) count was 3.1 (2.1–5.6) at LET initiation which increased to 5.1 (3.9–7.2) at the end of follow‐up ( p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationCytomegalovirus InfectionsValganciclovirAntiviral AgentsTransplant RecipientsCytomegalovirusAcetatesHumansMaleFemaleMiddle AgedRetrospective StudiesAdultQuinazolinesTreatment OutcomeAged

Stichwörter der Autor:innen

antiviralletermovirleukopeniareactivationtransplantation

Substanzen

ValganciclovirAntiviral AgentsletermovirAcetatesQuinazolines

Autor:innen und Institutionen

  • Department of Pharmacy Services, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
  • Division of Transplant Pulmonology, Norton Thoracic Institute, Dignity Health, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
  • Department of Pharmacy Practice, Midwestern University College of Pharmacy, Glendale, Arizona, USA.

ORCID-Profile: Sydni Martinez, Devika Sindu, Lauren Cherrier, Sofya Tokman, Rajat Walia, Kellie J Goodlet

Zitieren

APA

Martinez, S., Sindu, D., Nailor, M. D., Cherrier, L., Tokman, S., Walia, R., & Goodlet, K. J. (2024). Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14279

Vancouver

Martinez S, Sindu D, Nailor MD, Cherrier L, Tokman S, Walia R, et al. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients. Transplant Infectious Disease. 2024. doi:10.1111/tid.14279

BibTeX
@article{Martinez2024,
  author = {Martinez, Sydni and Sindu, Devika and Nailor, Michael D and Cherrier, Lauren and Tokman, Sofya and Walia, Rajat and Goodlet, Kellie J},
  title = {Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients},
  journal = {Transplant Infectious Disease},
  year = {2024},
  doi = {10.1111/tid.14279}
}
Kostenlos starten →